immunity News and Research

RSS

New COVID-19 vaccine promises vaccine equity because it has no patents

Corbevax, a new vaccine against COVID-19, may have better success as a candidate for vaccine equity because it carries no patents, relies on long-established recombinant technology for manufacture and has the support of the US and Indian governments, its makers and health experts say.

21 Jan 2022

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

In their recent study posted to the preprint server bioRxiv*, the researchers from China have shown that tuftsin, a natural phagocytosis-stimulating peptide, can effectively impair the binding of SARS-CoV-2 spike S1 subunit to ACE2 receptor in a dose-dependent manner and therefore can be considered a potential drug against SARS-CoV-2 infection.

20 Jan 2022

Research shows benefits of hybrid immunity to SARS-CoV-2

Researchers examine the effects of previous SARS-CoV-2 infections on the immunity offered by SARS-CoV-2 vaccination.

20 Jan 2022

SARS-CoV-2 breakthrough infections elicit potent neutralizing antibody responses

A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2.

20 Jan 2022

MD Anderson and Yingli Pharma announce strategic alliance to advance many oncology programs

The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.

20 Jan 2022

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

In a new study, scientists focused on the SARS-CoV-2 Beta variant and used computational methods to design and develop effective glycoprotein multi-epitope subunit vaccine candidates, based on the old and the new Beta virus strains.

20 Jan 2022

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

A new study aimed to understand the risk of COVID-19 infection given certain serological parameters, in a group of vaccinated healthcare workers with high rates of exposure to the virus, followed up at 9 months from vaccination.

20 Jan 2022

Study finds Omicron infection effectively induces immunity against itself and enhances protection against other variants in vaccinated individuals

Researchers investigated the effectiveness of the SARS-CoV-2 Omicron-variant induced immunity, whether it is cross-protective against other variants, and if earlier infection with the SARS-CoV-2 Delta variant offers protection against Omicron.

20 Jan 2022

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

In a new study, researchers discuss the role of calcium signaling pathways as targets of inhibition in potential new antiviral therapeutic pathways for SARS-CoV-2.

20 Jan 2022

SARS-CoV-2 Omicron infections milder in children compared to Delta

The clinical severity of COVID-19 was found to be lower in children younger than five years of age after the emergence of SARS-CoV-2 Omicron variant.

20 Jan 2022

A novel assay for the rapid detection of SARS-CoV-2 variants

A new study discusses a new assay method designed by researchers to identify SARS-CoV-2 variants.

20 Jan 2022

Research shows a relationship between increased SARS-CoV-2 seroreactivity and antimalarial humoral immunity

Researchers investigate the cross-reactivity of the SARS-CoV-2 with pre-pandemic malaria-exposed sera samples collected from Cambodia.

19 Jan 2022

Exploring the interactions between multiple respiratory viruses

A recent report explores the dynamics of viral interference between various respiratory viruses in light of the ongoing COVID-19 pandemic.

19 Jan 2022

Novel antibody that targets the N-terminal domain of SARS-CoV-2 identified

A new study discusses the targeted discovery of NTD-reactive antibodies from an individual who had recovered from SARS-CoV-2 infection.

19 Jan 2022

Emerging nanomaterials-based biosensor for detecting SARS-CoV-2

A new study aimed to highlight the different smart and emerging nanomaterials used to detect SARS-CoV-2.

19 Jan 2022

Study reports of receptor-binding domain multimer capable of enhancing the immune response against SARS-CoV-2

Researchers have discovered a new way to induce immunity against the RBD.

19 Jan 2022

Three doses Of Pfizer-BioNTech vaccine could offer sufficient level of protection from Omicron

A new study that evaluated the effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the Omicron variant indicates that three doses could offer a sufficient level of protection from disease caused by the Omicron variant.

18 Jan 2022

Study finds COVID booster maintains strong T cell response against Omicron

New study results posted to the medRxiv* preprint server found that COVID vaccine boosters increase immunity by enhancing T cell immune memory. In the face of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) Omicron variant, vaccinated people who had received a third booster shot maintained high T cell responses than people with naturally acquired immunity or vaccine-induced immunity from two doses of the SARS‑CoV‑2 vaccine.

18 Jan 2022

New perspective on SARS-CoV-2 breakthrough infections and booster shot restoration of vaccine efficacy

A recent article published in the journal Science explains how SARS-CoV-2 variants can bypass vaccine-induced immune defenses. However, immunity is restorable with a booster shot. The paper's authors outlined the importance of a booster shot in maintaining immunity and preventing severe infection.

18 Jan 2022

Exploring the viral dynamics of SARS-CoV-2 Omicron variant

In a new study, researchers posted findings in which they investigated the viral dynamics of the SARS-CoV-2 Omicron variant.

18 Jan 2022

immunity News and Research

New COVID-19 vaccine promises vaccine equity because it has no patents

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

Research shows benefits of hybrid immunity to SARS-CoV-2

SARS-CoV-2 breakthrough infections elicit potent neutralizing antibody responses

MD Anderson and Yingli Pharma announce strategic alliance to advance many oncology programs

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

Study finds Omicron infection effectively induces immunity against itself and enhances protection against other variants in vaccinated individuals

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

SARS-CoV-2 Omicron infections milder in children compared to Delta

A novel assay for the rapid detection of SARS-CoV-2 variants

Research shows a relationship between increased SARS-CoV-2 seroreactivity and antimalarial humoral immunity

Exploring the interactions between multiple respiratory viruses

Novel antibody that targets the N-terminal domain of SARS-CoV-2 identified

Emerging nanomaterials-based biosensor for detecting SARS-CoV-2

Study reports of receptor-binding domain multimer capable of enhancing the immune response against SARS-CoV-2

Three doses Of Pfizer-BioNTech vaccine could offer sufficient level of protection from Omicron

Study finds COVID booster maintains strong T cell response against Omicron

New perspective on SARS-CoV-2 breakthrough infections and booster shot restoration of vaccine efficacy

Exploring the viral dynamics of SARS-CoV-2 Omicron variant

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News